Jonathan Edward McConathy MD, PhD, Presenter: Speakers Bureau, Eli Lilly and Company Research Consultant, Eli Lilly and Company Research Consultant, General Electric Company Research Consultant, Blue Earth Diagnostics Ltd Research Consultant, Siemens AG

1) Understand key molecular and metabolic targets for PET imaging in oncology. 2) Be familiar with novel PET tracers that are promising for translation into human oncologic imaging studies.

Positron emission tomography (PET) with the glucose analogue 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) has established molecular imaging as an important aspect of clinical oncology but only probes one facet of cancer metabolism. A wide range of small molecule, peptide, antibody, and nanoparticle-based PET tracers are in development for oncologic imaging and can provide important insights into tumor biology. This talk will focus on novel PET tracers that have high translational potential to diagnose, stage, and direct therapy in oncology.

McConathy, J, Use of Novel PET Agents to Probe Tumor Biology: From Benchtop to the Clinic.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004188.html